MedTrace Logo

Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2020-12-19

No results posted yet for this study

Summary

This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.

Conditions

  • Persistent Asthma

Interventions

DRUG

QAW039 capsules once daily for 28 days

DRUG

Placebo to QAW039 capsules once daily for 28 days

DRUG

Fluticasone propionate inhaler twice daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States
  • Belgium
  • Germany
  • Romania
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253603 on ClinicalTrials.gov